Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · The Lancet Oncology · 2009 · 4.1K citations

Medicine, Oncology, Pharmacology +15

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>

Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson et al. · Journal of Clinical Oncology · 2009 · 1.9K citations · Full text

Medicine, Genetics, Oncology +17

<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu et al. · Clinical Cancer Research · 2008 · 983 citations · Full text

Medicine, Oncology, Pharmacology +17

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

Benjamin Solomon, Marileila Varella‐Garcia, D. Ross Camidge · Journal of Thoracic Oncology · 2009 · 340 citations · Full text

Medicine, Molecular Biology, Oncology +16

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

Tsuyoshi Takahashi, Makoto Sonobe, Masashi Kobayashi et al. · Annals of Surgical Oncology · 2009 · 323 citations

Medicine, Molecular Biology, Oncology +16